Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 53 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency MOST POPULAR Drug Combination May Have Potential for Cancers with TP53 Mutations April 4, 2024 Diving into our role in 50 top cancer drugs February 9, 2022 Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker November 23, 2021 New on NCI’s Websites for December 2021 December 29, 2021 Load more HOT NEWS Coronavirus reports – Part 6 “The kids being home all the... Workout Wednesday – Leg Stretches Part 1 Girls Become Best Friends In Hospital, Reunite Years Later For “Survivors”... New Class of Compounds Rewires Cancer Cells to Self-Destruct
